Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cyclopharm Limited ( (AU:CYC) ) just unveiled an announcement.
Cyclopharm Limited has lodged its latest corporate governance statement for the year ended 31 December 2025, confirming that the document is current as at that date and has been approved by the board. The statement, published on the company’s website under the Cyclomedica corporate section, details the extent of the group’s adherence to the ASX Corporate Governance Council’s principles and recommendations.
The filing, made alongside a completed Appendix 4G, indicates that Cyclopharm follows a broad range of governance practices, including a formal board charter, pre-appointment checks for directors and senior executives, written agreements for key personnel and direct accountability of the company secretary to the board. The lodgement underscores the company’s efforts to maintain regulatory compliance and transparency for investors under ASX Listing Rules 4.7.3, 4.7.4 and 4.10.3.
The most recent analyst rating on (AU:CYC) stock is a Sell with a A$0.68 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
More about Cyclopharm Limited
Cyclopharm Limited operates in the medical technology and healthcare sector, with its business conducted under the Cyclomedica brand. The company focuses on specialised diagnostic products and related services for nuclear medicine and respiratory imaging, targeting hospitals, clinics and other healthcare providers in domestic and international markets.
Average Trading Volume: 140,307
Technical Sentiment Signal: Sell
Current Market Cap: A$89.39M
Learn more about CYC stock on TipRanks’ Stock Analysis page.